Allarity Therapeutics Presents Stenoparib Ovarian Cancer Trial at ESMO Congress

Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026, held June 17–19 in Copenhagen, Denmark. The poster outlines the study design and clinical rationale for the company's ongoing Phase 2 trial evaluating stenoparib (2X-121) in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer.

The poster, titled "NCT03878849: A phase II trial of stenoparib/2X-121, a novel dual inhibitor of PARP and the WNT pathway, in platinum resistant/ineligible ovarian cancer patients," will be presented on June 18, 2026, by the study's Principal Investigator, Kathleen N. Moore, M.D., an internationally recognized specialist in gynecologic oncology. The company said the poster presentation places the ongoing Phase 2 study before a focused audience for gynecologic oncology in the U.S. and Europe. The poster will be available on the company's website following the presentation.

The ovarian cancer trial builds directly on Allarity's prior Phase 2 clinical experience, including durable clinical benefit observed in heavily pretreated ovarian cancer patients. Updated data from that earlier study were presented at the AACR special conference on advances in ovarian cancer in September 2025, with median overall survival surpassing 25 months. The amended protocol enrolls only platinum-resistant or platinum-ineligible patients and is designed to accelerate clinical development toward FDA approval. A new protocol began enrolling patients in the summer of 2025.

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases play a role in regulating the WNT signaling pathway, and aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, especially drug-resistant cancers. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. The FDA granted Fast Track designation to stenoparib for advanced ovarian cancer in August 2025.

In a separate clinical program, Allarity announced on February 18, 2026, that the first patients had been dosed with stenoparib in combination with temozolomide in a VA-funded investigator-initiated Phase 2 trial for the treatment of relapsed small cell lung cancer (SCLC). The trial is being conducted in collaboration with the U.S. Department of Veterans Affairs and is fully funded through the VA's Special E... The trial is open for enrollment at 11 VA medical centers nationwide.

Relapsed SCLC represents an area of high unmet medical need. Only about 40% of relapsed SCLC patients receive second-line therapy, and the median second-line treatment duration is under two months. Earlier-generation PARP inhibitors showed dose-limiting hematologic toxicity in this setting. Stenoparib is reported to cross the blood-brain barrier, and the combination with temozolomide aims to enhance efficacy while potentially reducing toxicity.

Stenoparib's dual PARP and WNT pathway inhibition mechanism shows potential across multiple cancer types, including ovarian cancer, small cell lung cancer, and colorectal cancer. Allarity completed its first Phase 2 trial for stenoparib in advanced ovarian cancer, which showed promising and durable clinical benefit in patients who had received two or more prior lines of therapy. The company's drug-specific DRP® patient selection approach is designed to help identify patients most likely to benefit from stenoparib therapy.